The newly published ISO 16921‑2:2026 standard—focused on quantification methods for viral vectors—now includes LumaCyte’s optical and fluidic force–based analytical approach, the core technology behind its Radiance® platform. This inclusion signals international validation of the method’s precision and relevance for measuring viral titers, a critical requirement in gene therapy and vaccine manufacturing.
LumaCyte has launched a groundbreaking cell therapy application for predictive CAR T donor analytics using their Laser Force Cytology™ (LFC™) technology and Radiance® instrument. This innovation provides deep insights into patient and donor cellular material, predicting manufacturing success and enhancing production consistency. LumaCyte also offers a new donor qualification service, allowing customers to send samples for analysis, aiming to revolutionize cell therapy by minimizing risks and increasing yields.
LumaCyte is launching the Laser Force Cytology™ Academy, an interactive library of training courses. This initiative aims to enhance understanding of their LFC™ technology and empower scientists and biomanufacturers in process development and production workflows.
LumaCyte has launched a compact version of their Radiance® instrument, now occupying only 16 inches of bench space. The advanced Laser Force Cytology™ (LFC) technology remains unchanged, catering to space-constrained biomanufacturing facilities.
LumaCyte announces the successful completion of A round financing that will allow the company to accelerate global growth, in addition to announcing the appointmentment of two industry executives, Paul M. Meister, and Peter L. Buzy, to its Board of Directors.
LumaCyte announces the addition of Jim Robinson to its Scientific Advisory Board (SAB). Jim brings more than 35 years of CMC vaccine manufacturing experience to the LumaCyte SAB, holding previous executive level positions at Merck, Sanofi Pasteur and Novavax.
LumaCyte launches European subsidiary, LumaCyte, B.V., in the Netherlands to serve as its hub for instrument sales and service in EMEA. Having resources close to our customers is critical for maintaining outstanding customer service and support.
LumaCyte recently collaborated with global cell and gene therapy leader, Catalent, where their joint teams uncovered valuable new capabilities in the monitoring of adeno-associated virus (AAV) production and infectivity, foundational precursors in the production of gene therapy products.
LumaCyte joins The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a Manufacturing USA institute sponsored by the National Institute of Standards and Technology (NIST).
© 2026 LumaCyte, Inc. All Rights Reserved.
